N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia

NCT04487951 | Unknown

• 1 other identifier: 2020-7-1
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to assess the difference between level of NT-pro-BNP, and Vitmin D in moderate cases who progressed to severe or critically ill category compared to those who did not. Assessment of any possible correlation between NT-pro-BNP and Vitamin D and the need for mechanical ventilation or mortality in COVID-19 infection.

Conditions

COVID19 Pneumonia

Keywords

NT-pro-BNP; Vitamin D; COVID-19 Pneumonia; HPLC/UV Diode array

Outcome Measures

Primary Outcomes (1)

• NT-pro-BNP and Vitamin D

  level of NT-pro-BNP, and Vitamin D

  6 month

Secondary Outcomes (1)

• Assessment of any possible correlation between NT-pro-BNP and Vitamin D and the need for mechanical ventilation or mortality in COVID-19 infection

  6 month

Study Arms (2)

Moderate

Moderate: moderate COVID -19 pneumonia

Other: Pro BNP , Vitamin D

Severe

\_severe COVID-19 pneumonia

Other: Pro BNP , Vitamin D

Interventions

Pro BNP , Vitamin D OTHER

This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.

Moderate; Severe

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study will be conducted on 100 COVID-19 confirmed patients Group (1): 50 mild to moderate cases (lung shadows without hypoxia and oxygen saturation \>92%) who progressed to severe illness characterized by hypoxia necessitating oxygen therapy, or critical illness characterized by respiratory failure necessitating mechanical ventilation either invasive or non-invasive within their hospital stay. Group (2): 50 mild to moderate cases who did not show clinical progression and were discharged.

You may qualify if:

• All cases will be diagnosed with COVID-19 by RT-PCR • Group (1) Critically ill patients: Respiratory Rate \> 30/min SaO2 \< 92% at room temperature Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours • Group (2) moderate cases: Patients has pneumonia manifestations on radiology associated with symptoms \&/or leucopenia or lymphopenia.

You may not qualify if:

• Other causes of pneumonia other than infection with SARS-CoV-2.
• Concomitant heart failure.
• Hypoxic patients on hospital admission.
• Arrhythmia.

Sponsors & Collaborators

• Cairo University: lead
• Kasr El Aini Hospital: collaborator

Study Sites (1)

Kasr Alainy Cairo University

Cairo, Giza Governorate, 11562, Egypt

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum samples

MeSH Terms

Interventions

Vitamin D

Intervention Hierarchy (Ancestors)

Secosteroids; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Study Officials

• Akram Abdelbary, Prof.

  Cairo University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Noha A. Radwan, Lecturer of Chemical pathology

CONTACT

01152003668; nohakhaled11@cu.edu.eg

Yasmine Elshiwy, Ass. Prof.

CONTACT

+201005002408; yasmineelshiwy@kasralainy.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Clinical and Chemical Pathology

Study Record Dates

• First Submitted: July 24, 2020
• First Posted: July 27, 2020
• Study Start: July 1, 2020
• Primary Completion: November 1, 2020
• Study Completion: January 1, 2021
• Last Updated: July 27, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)